Definition/General

Introduction:
-Sertoli cell tumor is a rare sex cord-stromal tumor composed purely of Sertoli cells
-Accounts for <1% of ovarian tumors
-Typically benign with excellent prognosis
-Shows tubular architecture without Leydig cells.
Origin:
-Originates from sex cord elements with pure Sertoli cell differentiation
-Shows testicular-type differentiation
-Contains tubular structures
-Usually non-functioning hormonally.
Classification:
-Pure Sertoli cell tumor (most common)
-Sertoli cell tumor with lipid storage
-Sclerosing Sertoli cell tumor
-Large cell calcifying Sertoli tumor
-Malignant Sertoli cell tumor (extremely rare).
Epidemiology:
-Peak incidence in young adults (2nd-3rd decade)
-Mean age 25-30 years
-Unilateral in >95% cases
-Benign behavior in majority
-Rare association with Peutz-Jeghers syndrome.

Clinical Features

Presentation:
-Asymptomatic pelvic mass (most common)
-Abdominal/pelvic pain
-No virilization (unlike Sertoli-Leydig tumors)
-Abdominal distension
-Normal menstrual cycles.
Symptoms:
-Pelvic mass (70-80%)
-Abdominal pain (40-50%)
-No hormonal effects typically
-Menstrual regularity maintained
-Asymptomatic (30-40%).
Risk Factors:
-Young age (reproductive years)
-Peutz-Jeghers syndrome (rare association)
-No established genetic factors
-No environmental associations
-Family history rare.
Screening:
-Pelvic ultrasound (solid mass)
-Tumor markers usually normal
-Hormonal assessment (usually normal)
-CT/MRI for characterization
-No specific tumor markers.

Master Sertoli Cell Tumor Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Solid, well-circumscribed mass
-Yellow to tan-gray cut surface
-Size ranges from 2-12 cm (average 5 cm)
-Lobulated appearance
-Firm consistency.
Characteristics:
-Unilateral in >95% cases
-Smooth capsule
-Cut surface shows solid homogeneous areas
-Yellow-tan color
-Firm consistency
-No hemorrhage or necrosis.
Size Location:
-Variable size (1-15 cm)
-Average size 4-8 cm
-No specific ovarian location preference
-Smaller than Sertoli-Leydig tumors
-Slow growth pattern.
Multifocality:
-Usually unifocal
-Bilateral involvement rare (<5%)
-No metastatic potential (benign cases)
-Associated with other tumors in Peutz-Jeghers syndrome.

Microscopic Description

Histological Features:
-Tubular structures lined by uniform cells
-Sertoli cells with oval nuclei
-Eosinophilic to clear cytoplasm
-Basement membrane present
-No Leydig cells in stroma.
Cellular Characteristics:
-Columnar to cuboidal cells
-Oval nuclei with fine chromatin
-Inconspicuous nucleoli
-Eosinophilic cytoplasm
-Low mitotic activity.
Architectural Patterns:
-Tubular pattern (classic)
-Solid nests (focal)
-Trabecular pattern
-Pseudopapillary areas
-Hyalinized stroma may be present.
Grading Criteria:
-Benign: No significant atypia, <2 mitoses/10 HPF
-Atypical: Moderate atypia, focal
-Malignant: Severe atypia, >2 mitoses/10 HPF, necrosis (extremely rare).

Immunohistochemistry

Positive Markers:
-Inhibin-alpha (90-95%)
-Calretinin (80-90%)
-SF-1 (steroidogenic factor)
-Vimentin
-CD99 (variable)
-Smooth muscle actin (focal).
Negative Markers:
-Cytokeratin (usually negative)
-EMA (negative)
-S-100 (negative)
-Chromogranin (negative)
-AFP (negative)
-Beta-hCG (negative).
Diagnostic Utility:
-Inhibin positivity confirms sex cord origin
-Calretinin supports diagnosis
-Distinguish from other sex cord tumors
-SF-1 confirms stromal origin.
Molecular Subtypes:
-STK11/LKB1 mutations (Peutz-Jeghers cases)
-Low mutation burden
-Similar to testicular Sertoli tumors
-Chromosomal stability.

Molecular/Genetic

Genetic Mutations:
-STK11/LKB1 mutations (Peutz-Jeghers syndrome)
-Sporadic cases - low mutation rate
-Chromosomal stability
-DICER1 mutations (rare).
Molecular Markers:
-Inhibin overexpression
-Sex cord gene expression
-Low Ki-67 proliferation index
-p53 wild-type.
Prognostic Significance:
-Excellent prognosis (benign cases)
-Complete excision curative
-No recurrence if completely excised
-Malignant potential extremely rare.
Therapeutic Targets:
-Surgical excision curative
-Enucleation possible
-Fertility-sparing surgery
-No adjuvant therapy needed.

Differential Diagnosis

Similar Entities:
-Sertoli-Leydig cell tumor (contains Leydig cells)
-Granulosa cell tumor (different morphology)
-Endometrioid carcinoma (epithelial markers)
-Carcinoid tumor (neuroendocrine markers).
Distinguishing Features:
-Sertoli cell: Pure Sertoli cells
-No Leydig cells
-Sertoli-Leydig: Contains Leydig cells
-Virilization
-Granulosa: Coffee-bean nuclei
-Call-Exner bodies
-Endometrioid: CK7 positive
-Epithelial features.
Diagnostic Challenges:
-Pure Sertoli vs mixed tumors
-Benign vs malignant assessment
-Complete sampling important
-Peutz-Jeghers association.
Rare Variants:
-Large cell calcifying Sertoli tumor
-Sclerosing Sertoli cell tumor
-Sertoli cell tumor with lipid
-Malignant Sertoli cell tumor.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

Ovarian mass, [side], measuring [X x Y x Z] cm

Diagnosis

Sertoli Cell Tumor

Classification

WHO Classification: Sex Cord-Stromal Tumor, Sertoli Cell Tumor

Histological Features

Shows tubular structures lined by uniform Sertoli cells without Leydig cell component

Special Studies

IHC: Inhibin-alpha [positive], Calretinin [positive], SF-1 [positive]

Final Diagnosis

Ovarian Sertoli Cell Tumor, [Side]